Tests flaxseed as an added diet treatment for adults with type 2 diabetes
Tests daily flaxseed powder with diet guidance in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Effect of Flaxseed as a Treatment for Adults With Type 2 Diabetes Mellitus in Mexico
Key facts
- Where
- Oaxaca City, MexicoSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 30 to 70 in Oaxaca with poorly controlled type 2 diabetes, to see how flaxseed affects blood sugar and blood fat markers.
- Age
- 30 to 70 years
- Sex
- Men and women
- Disease stage
- Type 2 diabetes diagnosed at most one year ago and not well controlled: fasting blood glucose greater than 140 and glycosylated hemoglobin greater than 6.5%, shown by tests done within the last month.
- Earlier treatment
- Must have attended the Nutrition outpatient clinic regularly for at least 3 consecutive months. Must not have a history of poor adherence to medicines.
- Biomarker or test result
- Fasting blood glucose greater than 140 and glycosylated hemoglobin greater than 6.5%, with results at most 1 month old.
Main reasons for not taking part
- Chronic kidney disease treated with renal function replacement therapy
- Blood sugar problems caused by autoimmune diabetes, thyroid disease or insulin-producing tumors
- Medical history of poor adherence to medicines
- Good blood sugar control shown by lab tests for at least 2 months
- Pregnant women with gestational diabetes
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 70 years old?
Source: NCT06683235, who can take part
Where in Mexico
- Hospital Regional Presidente JuárezOaxaca City, MexicoNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Universidad Autónoma Benito Juárez de Oaxaca
- Trial code
- NCT06683235
- Record updated
- 12 November 2024
- Original description
Type 2 Diabetes Mellitus represents one of the most important health emergencies of this century Although it is known that insulin resistance is reversible and that type 2 diabetes mellitus is controllable with a change towards a healthy lifestyle, the population ignores these recommendations and continues with their unhealthy habits. Thus, the number of patients continues to grow exponentially, which leads to an increase in economic expenditure on health. This is why non-pharmacological measures are sought that favor the reduction of glycemia in patients with Diabetes Mellitus where the consumption of functional foods is a good alternative for the treatment of this chronic disease. Flaxseed is a food characterized by its nutritional properties, highlighting its content of alpha linoleic acid, flax lignans, and secoisolariciresinol diglucosides. The latter have antioxidant, lipid-lowering and hypoglycemic effects, which makes it an excellent option as a functional treatment for type 2 diabetes.Read full original descriptionShow less
Effect of Flaxseed Consumption as a Treatment for Adults With Type 2 Diabetes Mellitus in Oaxaca de Juárez, Oaxaca
Type 2 Diabetes Mellitus represents one of the most important health emergencies of this century Although it is known that insulin resistance is reversible and that type 2 diabetes mellitus is controllable with a change towards a healthy lifestyle, the population ignores these recommendations and continues with their unhealthy habits. Thus, the number of patients continues to grow exponentially, which leads to an increase in economic expenditure on health. This is why non-pharmacological measures are sought that favor the reduction of glycemia in patients with Diabetes Mellitus where the consumption of functional foods is a good alternative for the treatment of this chronic disease. Flaxseed is a food characterized by its nutritional properties, highlighting its content of alpha linoleic acid, flax lignans, and secoisolariciresinol diglucosides. The latter have antioxidant, lipid-lowering and hypoglycemic effects, which makes it an excellent option as a functional treatment for type 2 diabetes.
The aim of this study is to assess the adjuvant effects of flaxseed consumption (14 gr of flaxseed) on biochemical markers (glucose, glycosylated hemoglobin, total cholesterol, triglycerides, LDL cholesterol and HDL cholesterol) in adult patients (30 to 70 years) with type 2 diabetes mellitus in Oaxaca.
Procedures Patients who sign the informed consent will be assigned a group according to the following: if they have an even number in their file, they will be part of the control group (A), and if they have an odd number, they will be part of the intervention group B.
Group A. They will be given a verbal instruction to continue with the treatment established by the treating physician, and they will be given nutritional guidance with the help of the healthy eating plate.
Group B. They will be given verbal instructions to continue with the treatment established by the treating physician, they will be given nutritional guidance with the help of the healthy eating plate and they will be given a leaflet with written instructions and photos on how to consume flaxseed and its benefits.
The researchers will purchase, package and provide the flaxseed powder to the members of group B. The flaxseed will be delivered in packages with 16 gr of ground flaxseed each, which will be given to the patients for daily consumption.
Inclusion: Oaxaca individuals between 30 and 70 years old; patients who attended the Nutrition outpatient clinic at the Oaxaca Hospital President "Benito Juárez" diagnosed at most one year ago and who agreed to participate in the study by signing the informed consent; Patients with a diagnosis of uncontrolled type 2 diabetes, evidenced by biochemical markers, with a maximum validity of 1 month (fasting blood glucose greater than 140 and glycosylated hemoglobin greater than 6.5%); Patients with regular attendance at the outpatient clinic, for at least 3 consecutive months.
Exclusion: Patients diagnosed with chronic kidney disease on renal function replacement therapy; Patients with a medical history of poor drug adherence; Patients who are pregnant and have gestational diabetes; Patients with glucose disorders secondary to autoimmune diabetes, thyroid diseases or insulin-producing tumors; Patients with adequate glycemic control evidenced by clinical laboratory tests for at least 2 months; Patients who do not have a means of contact for follow-up.